Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease of the nose and paranasal sinuses, predominantly mediated by type 2 inflammation and often associated with bronchial asthma and/or aspirin intolerance. It is a debilitating disease with substantial impact on the patient's quality of life and significant healthcare costs. Over the years, management strategies have mainly focused on symptom control and in cases of non-control, functional endoscopic sinus surgery (FESS) is considered. Despite maximal appropriate medical and surgical treatment, a significant percentage of patients do not achieve disease control. Today the treatment of the disease has changed thanks to the advent of new biological drugs. In the context of chronic diseases, including asthma and nasal polyposis, there is an increasing emphasis on achieving superior therapeutic outcomes. Remission, understood as the disappearance of symptoms and the restoration of normal clinical findings, becomes a key objective in clinical management. There are several monoclonal antibodies with the indication for nasal polyposis and choosing the right drug for the right patient is very important. The objective of this workshop is to provide scientific knowledge and all the useful elements for the correct management of the disease, promoting a vision oriented towards increasingly ambitious
objectives such as long-term control of the disease and sustained remission over time.
